Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.45 |
| ▸ | CSF1R | P07333 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | S100B | P04271 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 4/20 | 0.37 |
| ▸ | DRD3 | P35462 | 3/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | DPP4 | P27487 | 1/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31738557 | 1.00 | HTT (0.47) | HTTKDM4ELRRK2CSF1RALDH1A1 | |
| SCHEMBL31587376 | 1.00 | HTT (0.47) | HTTKDM4ELRRK2CSF1RALDH1A1 | |
| SCHEMBL23850784 | 1.00 | HTT (0.47) | HTTKDM4ELRRK2CSF1RALDH1A1 | |
| SCHEMBL31588227 | 0.84 | GAA (0.41) | HTTKDM4ELRRK2ALDH1A1GAA | |
| SCHEMBL23851980 | 0.84 | GAA (0.41) | HTTKDM4ELRRK2ALDH1A1GAA | |
| SCHEMBL23851235 | 0.84 | SMARCA2 (0.46) | HTTKDM4ELRRK2ALDH1A1GAA | |
| SCHEMBL31587445 | 0.84 | SMARCA2 (0.46) | HTTKDM4ELRRK2ALDH1A1GAA | |
| SCHEMBL23851634 | 0.84 | SMARCA2 (0.46) | HTTKDM4ELRRK2ALDH1A1GAA | |
| SCHEMBL23851233 | 0.84 | SMARCA2 (0.46) | HTTKDM4ELRRK2ALDH1A1GAA | |
| SCHEMBL31588159 | 0.84 | SMARCA2 (0.46) | HTTKDM4ELRRK2ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230064417-A1 | COMPOUNDS | Grey Wolf Therapeutics Limited (GB) | 2023-03-02 | — | — | US | disclosed |
| EP-3883650-A1 | COMPOUNDS | Grey Wolf Therapeutics Limited (GB) | 2021-09-29 | — | — | EP | disclosed |
| CN-113056305-A | Compound (I) | 格雷沃尔夫治疗有限公司 | 2021-06-29 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230064417-A1 | COMPOUNDS | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HRH4, CBR3 | HTT 297/4885KDM4E 2853/4885LRRK2 1016/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.